source
- J&J's Talvey plus Darzalex Faspro cuts death risk by up to 53% in relapsed multiple myelomaJohnson & Johnson reported that a combination of its immunotherapy Talvey with Darzalex Faspro, with or without Pomalyst, significantly lowered the risk of death in patients with relapsed or refrac…
- CMS proposes rule to close Medicare negotiation loophole for biologicsCMS announced a proposed policy change that would clarify how the Centers for Medicare & Medicaid Services groups products for price negotiations under the Inflation Reduction Act. The rule target…